

Translating Biomedical Innovations: the collaborative challenge

Dr John F Stageman

Chairman of Bionow & the UK HealthTech Medicines Knowledge Transfer Network

Collaborative Partnerships in Health, Medicine & Social Care Conference:
Lancaster

18th September 2012

Life-Science research and innovation: a global UK strength!

- Public Sector Investment in life-sciences & high international competitive quality
- Health related charity investment
- Established industry & SME R&D investment
- NHS (especially NIHR)

Principle sources of invention and innovation

- Universities
- Research Institutes
- Industry (especially SMEs)
- NHS / Hospitals

Complimentary strengths across the innovation pathway

	Latest Science & Tech	Perceive Application	Translational Capacity	Development Capacity	Investment Capacity	Speed of Action	Patient access & understanding	Global Market knowledg
Universities & Institutes	Y	?	?	X	X	X	?	X
Industry	Y?	Y?	Y?	Y	Y?	Y	X	Y
NHS	?	Y	Y?	X	X	X	Y	X

Self-evident need to collaborate!!

Changing drivers for innovation

- Unmet patient need & emerging threats to health
- Demographics & rising expectations
- Advances in Science & Technology
- Increasing need for cost efficiency & value for money
- Perceived benefit & improved societal / global outcome

Additional classes of valuable innovations

- Therapies
- Diagnostics
- Devices
- Medical Technologies
- 'E' & 'Tele' health applications
- Communication & monitoring tools
- Assisted Living / QOL aids
- Preventive & compliance aids
- Data analysis & exploitation

HMG recognises the strategic importance of this sector to the UK economy!

- New Life-Science strategy & plans (December 2011)
- Uptake & Adoption of Innovation in the NHS (Nicholson review / implementation ongoing)
- NIHR investment in Clinical Trials infrastructure, TRPs and E-Health resources
- Introduction of new interventions across the innovation pathway e.g.
 - R&D tax credits
 - Biomedical Catalyst
 - Patent Box

Encouraging Industry to collaborate

- Be simple and clear about what is on offer
- Offer a 'one stop shop' if possible
- Appreciate that industry timescales are often tight
- Understand the companies strategy and priorities
- Achieve a common perception of outcome & value
- Transparent costs
- Invest in personal relationships
- Excellent project management

Overcoming the barriers to collaboration

- Avoiding traditional suspicions & prejudices
- Appreciating the issues caused by short-term pressures
- Silo thinking & decision making
- Developing a common perception of value & attrition
- Real risk / value sharing
- Clear mechanisms for IP attribution

Actively encourage interchange to broaden careers & optimise education & training

Biomedical Catalyst

- Major new initiative to accelerate the translation of best biomedical innovations from academic or commercial sector through to investable companies
- £180m funding jointly administered by the TSB and MRC
- Aims to “target the valley of death” experienced at the earlier stages of translation
- 3 broad classes of award ‘Feasibility’, ‘Early-Stage’, ‘Late-Stage’
- Want to encourage widest range of biomedical innovations
- Syndication / Risk sharing with private investors encouraged
- Partnership with NIHR / NOCRI infrastructure & research investments also strongly encouraged